FOLH1 and prostate carcinoma: In recent years, PSMA-targeting positron emission tomography (PET) imaging, primarily using the radiolabeled urea-based small molecular PSMA inhibitors 68Ga-PSMA-HBED-CC and 18F-DCFPyL, has emerged as an important modality for imaging prostate carcinomas with promising clinical results, leading to an increase in the number of studies exploring the role of PSMA PET in detection, staging, restaging at biochemical recurrence, prognostication, and treatment response assessment of prostate carcinoma [5].